Abstract
Background Most studies of the epidemic cycles of the pandemic of Sars-CoV-2, or COVID-19 as it became known, define the beginning of specific cycles in countries from the laboratory identification of the first cases of infection, however, there is the awareness that cycles may have started earlier, without proper identification. This influences all the parameters that govern the statistical models used for controlling the infection.
Purpose This work proposes two models based on experimental data. The Logistic Model it is used to obtain three parameters of the epidemic cycle of COVID-19, namely: the final count for the total infected, the daily infection rate and the lag time. Complimentary, a novel inventory model is proposed to calculate the number of infective persons, as well as to determine the incubation period.
Methods The data on epidemic cycles of Germany, Italy, and Sweden are treated previously by the Moving Average Method with Initial value (MAMI), then a variation of the Logistic Model, obtained through curve-fitting, is used to obtain the three parameters. The inventory model is introduced to calculate the actual number of infected persons and the behavior of the incubation period is analyzed.
Results After comparing data from the three countries it is possible to determine the actual probable dates of the beginning of the epidemic cycles for each one, determine the size of the incubation period, as well as to determine the total number of infective persons during the cycle.
Conclusions The actual probable dates of the beginning of the epidemic cycles in the countries analyzed are determined, the total number of infected is determined, and it is statistically proven that the incubation cycle for Sars-CoV-2 is five days.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Exemption: no individual data, only public data.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
1
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos